Robert Krysiak1, Małgorzata Gilowska1,2, Bogusław Okopień1. 1. Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland. 2. Department of Cardiology, Provincial Hospital, Bielsko-Biała, Poland.
Abstract
BACKGROUND: Vitamin D is suggested to reduce cardiovascular risk. HYPOTHESIS: Circulating levels of plasma lipids and other cardiovascular risk factors may differ between statin-treated patients with different vitamin D status. METHODS: We studied 3 age- and weight-matched groups of men with elevated low-density lipoprotein cholesterol (LDL-C) levels: vitamin D-naïve men with vitamin D insufficiency (group A, n = 18), men with vitamin D deficiency/insufficiency effectively treated with vitamin D preparations (group B, n = 16), and vitamin D-naïve men with normal vitamin D status (group C, n = 16). All patients were then treated with atorvastatin (20 mg daily) for 4 months. Plasma lipids, glucose homeostasis markers, and plasma levels of uric acid, high-sensitivity C-reactive protein (hsCRP), homocysteine, and fibrinogen were assessed before and at the end of atorvastatin therapy. RESULTS: Study groups did not differ in baseline levels of plasma lipids. Men with vitamin D deficiency or insufficiency effectively treated with vitamin D preparations were characterized by decreased insulin sensitivity and higher circulating levels of hsCRP, homocysteine, and fibrinogen in comparison with the remaining groups of patients. Although atorvastatin decreased plasma levels of total cholesterol and LDL-C to a similar extent in all study groups, its effect on uric acid, hsCRP, homocysteine, and fibrinogen was more pronounced in patients from groups B and C than in men from group A. Moreover, in patients with vitamin D insufficiency, atorvastatin impaired insulin sensitivity. CONCLUSIONS: The obtained results indicate that the strength of pleiotropic effects of atorvastatin depends on vitamin D status.
BACKGROUND:Vitamin D is suggested to reduce cardiovascular risk. HYPOTHESIS: Circulating levels of plasma lipids and other cardiovascular risk factors may differ between statin-treated patients with different vitamin D status. METHODS: We studied 3 age- and weight-matched groups of men with elevated low-density lipoprotein cholesterol (LDL-C) levels: vitamin D-naïve men with vitamin Dinsufficiency (group A, n = 18), men with vitamin Ddeficiency/insufficiency effectively treated with vitamin D preparations (group B, n = 16), and vitamin D-naïve men with normal vitamin D status (group C, n = 16). All patients were then treated with atorvastatin (20 mg daily) for 4 months. Plasma lipids, glucose homeostasis markers, and plasma levels of uric acid, high-sensitivity C-reactive protein (hsCRP), homocysteine, and fibrinogen were assessed before and at the end of atorvastatin therapy. RESULTS: Study groups did not differ in baseline levels of plasma lipids. Men with vitamin Ddeficiency or insufficiency effectively treated with vitamin D preparations were characterized by decreased insulin sensitivity and higher circulating levels of hsCRP, homocysteine, and fibrinogen in comparison with the remaining groups of patients. Although atorvastatin decreased plasma levels of total cholesterol and LDL-C to a similar extent in all study groups, its effect on uric acid, hsCRP, homocysteine, and fibrinogen was more pronounced in patients from groups B and C than in men from group A. Moreover, in patients with vitamin Dinsufficiency, atorvastatinimpaired insulin sensitivity. CONCLUSIONS: The obtained results indicate that the strength of pleiotropic effects of atorvastatin depends on vitamin D status.
Authors: Kiran K Khush; David D Waters; Vera Bittner; Prakash C Deedwania; John J P Kastelein; Sandra J Lewis; Nanette K Wenger Journal: Circulation Date: 2007-01-29 Impact factor: 29.690